Longevity & AgingGLP-1 Drugs Like Ozempic May Protect the Aging Brain From Neurodegeneration
A comprehensive 2026 review in the Journal of Clinical Investigation evaluates GLP-1 receptor agonists (GLP-1RAs) — drugs like semaglutide and liraglutide used for diabetes and obesity — as potential disease-modifying therapies for neurodegenerative diseases including Alzheimer's, Parkinson's, ALS, Huntington's, and multiple sclerosis. The authors synthesize preclinical, epidemiological, and early clinical trial evidence showing that GLP-1RAs target multiple shared disease hallmarks: pathological protein aggregation, mitochondrial dysfunction, neuroinflammation, synaptic loss, and gut-brain axis dysregulation. While preclinical evidence is robust and epidemiological signals are promising, clinical trial results remain mixed, and key questions around brain penetrance, optimal dosing, patient selection, and biomarker validation persist.
